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A B S T R A C T
We herein report a case of Werner’s syndrome (WS) with cardiac syndrome X (CSX) and heart failure
with preserved ejection fraction (HFpEF), receiving nicorandil treatment.
A 58-year-old woman with chest discomfort on exercise was suspected of having effort-angina pectoris
because of broad ST-depression in electrocardiogram of exercise test and reversible defect in the
posterior-wall portion of left ventricle in exercise thallium201 myocardial scintigraphy. This patient also
exhibited HFpEF, diagnosed by increased ratio of early-transmitral-ﬂow-velocity to tissue-Doppler
early-diastolic mitral annular velocity (E/e0) in echocardiography and plasma B-type natriuretic peptide
(BNP) levels. However, coronary angiography revealed no organic stenosis in epicardial coronary
arteries, and coronary physiological measurements by PressureWireTM (St. Jude Medical, St Paul, MN,
USA) demonstrated that coronary ﬂow reserve (CFR) was greatly decreased. Because impaired CFR
represents coronary microvascular dysfunction in the absence of obstructive coronary narrowing, we
diagnosed CSX, and initiated the administration of nicorandil to improve coronary microcirculation.
After three-month-treatment of nicorandil, the patient’s symptoms were diminished, and reversible
defect in exercise myocardial scintigraphy was improved. Furthermore, both E/e0 and BNP were
decreased, indicating the improvement of HFpEF via the restoration of microvascular dysfunction.
Thus, nicorandil administration could bring beneﬁcial effects in WS with CSX and HFpEF, accompanied
by coronary microcirculation dysfunction.
<Learning objective: Contrary to previous case reports regarding Werner’s syndrome (WS) with
obstructive coronary artery disease (CAD), we herein report a case of WS with cardiac syndrome X (CSX)
without obstructive CAD, complicated with heart failure with preserved ejection fraction (HFpEF).
Because impaired coronary microcirculation is known to be associated with left ventricular hypertrophy
and HFpEF, nicorandil could improve not only CSX but HFpEF via the restoration of coronary
microvascular dysfunction.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Werner’s syndrome (WS) is an autosomal recessive hereditary
disease whose major symptom is the onset of early aging. Since
this syndrome was ﬁrst reported in 1904 by Otto Werner* Corresponding author at: Department of Cardiovascular Medicine, Kumamoto
University Graduate School of Medical Sciences, 1-1-1 Honjo, Kumamoto 860-8556,
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sooner than their actual ages, additional WS case reports have
accumulated worldwide, the majority being from Japan [1]. The
main causes of death in WS are generally malignant tumors and
atherosclerotic diseases including cerebral and myocardial infarc-
tion, and the average age of death is 54 years [2].
Case report
A 58-year-old woman suffering from WS, who had a short
stature of 146 cm, complained of chest discomfort and pain, and reserved.
Fig. 1.
Bull’s eye images of exercise thallium201 myocardial scintigraphy,
indicating exercise-induced myocardial ischemia in left ventricle
posterior wall (red arrow). Upper panel, exercise-phase; lower panel,
rest-phase.
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admission. She had gray hair since junior-high school, a cataract
at age 18 years, and a surgical partial thyroidectomy for thyroid
tumor when she was 23 years old. She lost her hair at the age of 46,
and had femoral head replacement therapy due to necrosis of bone.
Furthermore, she had refractory skin ulcer since she was 49 years
old, and diagnosed to have WS from her typical symptoms of this
skin disease. The diagnosis was conﬁrmed by the test of genomic
DNA, by the ﬁnding of homozygous G to C mutation at the junction
of intron 25 and exon 26 of WRN gene, which is the most common
in Japanese WS patients [3].
In order to evaluate the atherosclerotic change of major arteries
systemically, we conducted cervical echography and magnetic
resonance angiography of cerebral, carotid, and lower-limb
arteries and aorta, but these studies showed no apparent
macrovascular atherosclerotic changes. By contrast, both brachi-
al-ankle pulse wave velocity (baPWV; right side: 2585 cm/s, left
side: 2701 cm/s) measured by ankle brachial index measurement
(BP-203RPE II; Omron Colin, Tokyo, Japan) and peripheral vascular
endothelial function estimated by Endo-PAT2000 (Itamar Medical,
Caesarea, Israel) as ﬁngertip reactive hyperemia peripheral arterial
tonometry index (RHI; 1.59) were impaired. Moreover, signiﬁcant
ST depressions were found in II, III, aVf, and V4–6 leads in
electrocardiogram of the treadmill exercise test with chest pain
symptoms, and exercise thallium201 myocardial scintigraphy
showed a reversible defect in the posterior wall portion of left
ventricle (LV), indicating exercise-induced myocardial ischemia
(Fig. 1). Thereafter, we initiated the administration of aspirin
100 mg/day, a b-blocker, bisoprolol 5 mg/day, and a hydroxy-
methylglutaryl coenzyme A reductase inhibitor, pitavastatin 2 mg/
day for her as the patient with effort angina pectoris (AP), but this
WS patient’s symptoms were not diminished. Ultrasound cardiog-
raphy revealed that the ratio of early transmitral ﬂow velocity to
tissue Doppler early diastolic mitral annular velocity (E/e0) was
22.2, LV wall motion had normal contraction [LV ejection fraction
(EF) estimated by modiﬁed Simpson method was 69.7%], and no
asynergy, indicating cardiac diastolic dysfunction without reduced
LVEF. Hence, we deﬁned this WS patient associated with heart
failure (HF) with preserved LVEF (HFpEF) according to the criteria
of the European Working Group [4]: (1) symptoms of HF; (2)
normal or mildly reduced LV systolic function (LVEF >50% and LV
end-diastolic volume index <97 mL/m2); and (3) evidence of
abnormal LV diastolic distensibility. To conﬁrm a diagnosis of
obstructive coronary artery disease (CAD) in this WS patient, we
then performed heart catheterization including coronary angiog-
raphy (CAG). However, CAG revealed that there was no organic
stenosis in epicardial coronary arteries including the left circum-
ﬂex coronary artery (LCX), which was considered to have
signiﬁcant stenosis from the results of above-mentioned thallium
scintigraphy (Fig. 2A). When there is no organic stenosis in
epicardial coronary artery, we generally perform coronary ﬂow
reserve (CFR) measurement only in left anterior descending
coronary artery (LAD) vessel, which has the greatest perfusion
territory among epicardial coronary arteries, under adenosine
triphosphate (ATP) provocation to estimate coronary microvascu-
lar function, because regions of cardiac microvascular dysfunction
are independent of blood supply from epicardial coronary arteries.
Hence, we further inserted PressureWireTM Certus (St. Jude
Medical, St Paul, MN, USA) to LAD, positioned in the distal more
than two-thirds of the LAD, and performed coronary physiological
measurements. The basal diastole-to-systole velocity ratio (DSVR)
and averaged peak velocity (APV) were 0.8 and 34 cm/s,
respectively before intracoronary injection of any cardiovascular
agents, and elevated to 1.4 and 41 cm/s, respectively after the
infusion of isosorbide dinitrate into left coronary artery. ATP for
2 min was then administered into central venous to induce steadystate maximal hyperemia, CFR was calculated as the ratio of
hyperemic to baseline APV. After 2 min infusion of 180 mg/kg/min
ATP, DSVR and APV were changed inversely to 0.9 and 31 cm/s,
revealing that CFR estimated in distal LAD was only 0.76. In the
absence of obstructive coronary narrowing, impaired CFR repre-
sents coronary microvascular dysfunction [5]. These data demon-
strated that coronary microcirculation was quite impaired without
epicardial coronary organic stenosis in this WS patient (Fig. 2B).
Furthermore, LAD ﬂow pattern in this case was atypical, and such
ﬂow pattern is often seen in right coronary artery. Similar ﬂow
pattern of LAD with RCA in this case could be induced by cardiac
diastolic dysfunction, because LAD ﬂow pattern in HFpEF without
right-sided cardiac disturbance has the possibility to be changed
by LV structural or mechanical remodeling. In addition, CFR was
completely abolished in LAD, hence reversible defect in the region
other than LCX could appear if myocardial scintigraphy was
performed under ATP provocation or greater exercise load.
Because we could not perform acetylcholine provocation test to
exclude coronary spastic angina (CSA) due to chronic kidney
disease, we performed a hyperventilation provocation (HV) test,
and found that this patient exhibited no symptom and no ST-T
change in electrocardiogram by HV test. Taken together with
typical chest pain on exertion for effort AP, this WS patient is
thought to have cardiac syndrome X (CSX), deﬁned as typical chest
pain, transient myocardial ischemia, and angiographically normal
coronary arteries with the result of heart catheterization.
Therefore, we administered the addition of 15 mg/day nicorandil
to improve coronary microcirculation. After three months of
treatment with nicorandil, exercise-induced symptoms were
Fig. 3.
The changes in myocardial scintigraphy before (left panel) and after
(right panel) the treatment with nicorandil in this Werner’s syndrome
patient.
Fig. 2.
(A) CAG revealed that there was no organic stenosis in epicardial coronary arteries. (B) DSVR and APV in LAD. Baseline (upper panel), post intracoronary injection
of ISDN (mid panel), and post intravenous infusion of ATP (lower panel). CAG, coronary angiography; DSVR, diastole-to-systole velocity ratio; APV, averaged peak
velocity; LAD, left anterior descending coronary artery; ISDN, isosorbide dinitrate; ATP, adenosine triphosphate.
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scintigraphy was improved as shown in Fig. 3. Nicorandil treat-
ment for this WS patient improved coronary microvascular
dysfunction and effort-induced myocardial ischemia without
epicardial coronary stenosis.
Discussion
Nicorandil, which acts both as a nitrate and an ATP-sensitive
potassium channel opener, dilates coronary resistance vessels [6],
and improves microcirculation. Also, nicorandil has been reported
to improve the prognosis not only of CAD, but also of chronic HF
patients [7]. In this case, nicorandil treatment decreased both E/e0
and B-type natriuretic peptide (BNP) values (before and three
months after treatment with nicorandil in E/e0, 22.2–14.8, and
before and three months after treatment with nicorandil in BNP,
353.7–49.4 pg/mL) in this WS patient. Although there is no direct
evidence of changes in microvascular function by nicorandil
treatment in this patient, these data suggested the possibility of
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microvascular-induced myocardial ischemia. However, further
clinical studies are required to elucidate whether nicorandil
treatment can improve LV diastolic dysfunction through its
beneﬁcial effects on microcirculation. After three months of
treatment with nicorandil, both baPWV and RHI values were
slightly improved, indicating the improvement in vascular
function by nicorandil in this WS patient. Camici et al. recently
reported that the coronary circulation and blood ﬂow were
decreased in an experimental model of LV hypertrophy, with
complicated cardiac diastolic function [8]. Hence, the improve-
ment in coronary microcirculation could be a useful therapeutic
strategy for HF with preserved LVEF, which has great clinical
importance in current clinical practice.
Although it is considered to resemble the normal aging, there
are some differences between normal aging and the symptoms of
WS. In normal aging, atherosclerosis is mainly in the major arteries
including aortas. On the contrary, atherosclerosis is observed in
small and peripheral arterioles in patients with WS. In this case,
relatively large arteries including cerebral, cervical, and coronary
arteries had no severe atherosclerotic plaques. Hence, the
impairments of not only coronary microcirculation but also
cardiac diastolic dysfunction in this case were possible to be
caused by arteriosclerosis, which is often common in WS patients.
Without acetylcholine provocation test during heart catheteriza-
tion, however, we could not distinguish whether microcirculation
dysfunction in this case was induced by coronary microvascular
organic change or by microvascular spasm. CSX is an important
clinical entity, and coronary microvascular abnormalities have
already been suggested to be the underlying pathophysiological
mechanism for CSX [9]. This case suggested nicorandil could
improve CSX via restoration of coronary microvascular dysfunction
in WS, because nicorandil was reported to improve not only
microvascular spasm but also atherosclerosis in end-stage renal
disease on hemodialysis, which is commonly complicated with
coronary microvascular dysfunction. Furthermore, it was possible
that other medicines such as calcium channel blockades or nitrates
were also possibly effective, if coronary microvascular dysfunction
was mainly induced by microvascular spasm.
Although there were some case reports of obstructive CAD
treated with any coronary interventions in WS patients [10], this is
the ﬁrst report of WS patients with CSX and cardiac diastolicdysfunction, accompanied by impaired coronary microcirculation.
Also, we suggested that nicorandil administration could bring
beneﬁcial effects in the case of WS with coronary microcirculation
dysfunction.
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